July 2023
Congratulations to Drs Miko Filon, Bing Yang and Tanaya Purohit, and the team for this first in field work to identify increased histone acetylation activity from circulating tumor cells in a subset of patients with advanced hormone-resistant prostate cancer. This personalized medicine approach will permit the targeted treatment of patients with the new generation of p300/CBP inhibitors being developed.
Journal reference:
Filon, M., et al. (2023) Development of a multiplex assay to assess activated p300/CBP in circulating prostate tumor cells. Oncotarget. doi.org/10.18632/oncotarget.28477.
In the June episode of UW Urology’s WInnovations podcast, Dr. David Jarrard, Professor and Vice Chair of UW’s Department of Urology, John P. Livesey Chair in Urologic Oncology, and Deputy Director of the UW Carbone Cancer Center discusses the prostate cancer treatment landscape and exciting advancements in the field with host, Dr. Kyle Richards. They also talk about the UW Carbone Cancer Center’s prostate cancer research Specialized Program of Research Excellence (SPORE) award announced last month – an over $11 million federal grant from the National Cancer Institute. Recorded 5/19/2023
“Treating Metastatic Prostate Cancer in 2022”
MaleCare Cancer Support Program
University Place | Diagnosing and Treating Prostate Cancer
PBS Wisconsin
David Jarrard, Professor, Department of Urology, UW School of Medicine and Public Health, addresses clinical questions about prostate cancer including why it is more frequent in an aging population, which cancers are dangerous and how to identify them. Jarrard discusses whether prostate cancer can be prevented.